Cite
HARVARD Citation
Groeneveld, C. et al. (2021). Tertiary lymphoid structures marker CXCL13 is associated with better survival for patients with advanced-stage bladder cancer treated with immunotherapy. European journal of cancer. pp. 181-189. [Online].